文献速递湿疹皮炎与荨麻疹

克立硼罗软膏2%在儿童和成人轻中度特应性皮炎中的长期安全性

Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
PubMed 文献 · J Am Acad Dermatol · 2017-08-18

本研究为多中心、开放标签、为期48周的安全性研究(AD-303),纳入517例≥2岁轻中度特应性皮炎患者,在完成28天III期关键研究后继续使用克立硼罗软膏。结果显示治疗相关不良事件发生率低,最常见为特应性皮炎、应用部位疼痛和应用部位感染,仅1.7%患者因不良事件停药。

要点

  • 克立硼罗软膏长期治疗48周治疗相关不良事件发生率低(总体10.2%)。
  • 最常见治疗相关不良事件为特应性皮炎(3.1%)、应用部位疼痛(2.3%)和应用部位感染(1.2%)。
  • 仅1.7%患者因不良事件退出长期研究。

核心结论

  • 克立硼罗软膏在轻中度特应性皮炎患者中治疗48周治疗相关不良事件发生率低。

研究设计与样本

  • 多中心、开放标签、48周安全性研究(AD-303),纳入517例≥2岁轻中度特应性皮炎患者,在完成28天III期关键研究(AD-301、AD-302)后继续治疗。

主要发现

  • 关键研究和AD-303期间,65%患者报告至少1例治疗中出现的不良事件,其中轻度占51.2%、中度占44.6%,93.1%被认为与治疗无关。
  • 治疗相关不良事件总体发生率为10.2%,最常见为特应性皮炎(3.1%)、应用部位疼痛(2.3%)和应用部位感染(1.2%)。
  • 9例患者(1.7%)因治疗中出现的不良事件退出长期研究。

临床怎么用

  • 克立硼罗软膏可用于≥2岁轻中度特应性皮炎患者的长期治疗,治疗相关不良事件风险较低。

局限性

  • 未分析长期疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term topical treatment is often required for atopic dermatitis (AD), a chronic inflammatory skin disease. OBJECTIVE: To assess the long-term safety results from a multicenter, open-label, 48-week safety study (AD-303) of patients (N = 517) ≥2 years of age with mild to moderate AD who continued crisaborole treatment, a topical phosphodiesterase-4 inhibitor, after completing a 28-day phase 3 pivotal study (AD-301, AD-302). METHODS: Global disease severity was assessed in patients every 4 weeks, and if assessed as mild or greater, a 28-day treatment period with crisaborole applied twice daily was initiated. Adverse events (AEs), including treatment-emergent AEs (TEAEs), and serious AEs were analyzed. RESULTS: During the pivotal studies and AD-303, 65% of patients reported ≥1 TEAE, most of which were mild (51.2%) or moderate (44.6%) and considered unrelated to treatment (93.1%). The frequency and severity of TEAEs were consistent. The most frequently reported treatment-related AEs (overall, 10.2%) were dermatitis atopic (3.1%), application-site pain (2.3%), and application-site infection (1.2%). Nine patients (1.7%) discontinued the long-term study because of TEAEs. LIMITATIONS: Long-term efficacy was not analyzed. CONCLUSION: Crisaborole ointment had a low frequency of treatment-related AEs over 48 weeks of treatment of patients with AD.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017. PMID: 28823881. doi:10.1016/j.jaad.2017.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。